Ph.D., M.S., Executive Vice President and Chief Technology Officer, Gritstone
Dr. Yelensky is responsible for overseeing Gritstone’s genomics, proteomics and informatics programs. Previously, he was vice president of biomarker and companion diagnostic development at Foundation Medicine. While there, he co-led sequence data analysis for FoundationOne™ and led validation studies supporting clinical laboratory accreditation and testing of more than 100,000 patients. Dr. Yelensky established Foundation Medicine’s FDA-regulated products program, leading to the FDA approval of FoundationFocusCDxBRCA, the first NGS-based companion diagnostic. He also contributed to key national initiatives on the clinical implementation of next-generation sequencing (NGS), leading the diagnostic implementation of Lung-MAP, a first-of-its-kind NCI-sponsored trial matching lung cancer patients to investigational treatments using comprehensive genomic testing. Prior to Foundation Medicine, Dr. Yelensky was a senior scientist in biomarker development at Novartis. He has co-authored more than 75 manuscripts on bioinformatics, statistical genetics, NGS biomarker and assay development and cancer genomics. He is an alumnus of Stanford University and the Harvard-MIT Division of Health Sciences and Technology.
Presentation Title and Company Description
Immunotherapy Showcase: Turning Tumor Antigens into Personalized Cancer Therapies
Gritstone Oncology is a cancer immunotherapy company working to help patients with the most difficult-to-treat tumors. We develop potent, next-generation, personalized immunotherapies that harness the power of the immune system to recognize and destroy cancer cells.